Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, January 20, 2022
[ Thu, Jan 20th 2022
] - WOPRAI
[ Thu, Jan 20th 2022
] - WOPRAI
[ Thu, Jan 20th 2022
] - WOPRAI
[ Thu, Jan 20th 2022
] - WOPRAI
[ Thu, Jan 20th 2022
] - WOPRAI
[ Thu, Jan 20th 2022
] - WOPRAI
[ Thu, Jan 20th 2022
] - WOPRAI
[ Thu, Jan 20th 2022
] - WOPRAI
[ Thu, Jan 20th 2022
] - WOPRAI
[ Thu, Jan 20th 2022
] - WOPRAI
[ Thu, Jan 20th 2022
] - WOPRAI
[ Thu, Jan 20th 2022
] - WOPRAI
[ Thu, Jan 20th 2022
] - WOPRAI
[ Thu, Jan 20th 2022
] - WOPRAI
[ Thu, Jan 20th 2022
] - WOPRAI
[ Thu, Jan 20th 2022
] - WOPRAI
[ Thu, Jan 20th 2022
] - WOPRAI
[ Thu, Jan 20th 2022
] - WOPRAI
[ Thu, Jan 20th 2022
] - WOPRAI
[ Thu, Jan 20th 2022
] - WOPRAI
[ Thu, Jan 20th 2022
] - WOPRAI
[ Thu, Jan 20th 2022
] - WOPRAI
[ Thu, Jan 20th 2022
] - WOPRAI
[ Thu, Jan 20th 2022
] - WOPRAI
[ Thu, Jan 20th 2022
] - WOPRAI
[ Thu, Jan 20th 2022
] - WOPRAI
[ Thu, Jan 20th 2022
] - WOPRAI
[ Thu, Jan 20th 2022
] - WOPRAI
[ Thu, Jan 20th 2022
] - WOPRAI
[ Thu, Jan 20th 2022
] - WOPRAI
Evan Seigerman Upgraded (VRTX) to Buy and Increased Target to $274 on, Jan 20th, 2022
Evan Seigerman of BMO Capital, Upgraded "Vertex Pharmaceuticals Incorporated" (VRTX) to Buy and Increased Target from $202 to $274 on, Jan 20th, 2022.
Evan has made no other calls on VRTX in the last 4 months.
There are 8 other peers that have a rating on VRTX. Out of the 8 peers that are also analyzing VRTX, 1 agrees with Evan's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Do Kim of "Piper Sandler" Downgraded from Buy to Hold and Decreased Target to $218 on, Friday, November 19th, 2021
These are the ratings of the 7 analyists that currently disagree with Evan
- Liisa Bayko of "Evercore ISI Group" Maintained at Buy and Held Target at $265 on, Wednesday, December 22nd, 2021
- Mohit Bansal of "Wells Fargo" Initiated at Buy and Held Target at $270 on, Thursday, December 9th, 2021
- Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy and Held Target at $275 on, Thursday, December 2nd, 2021
- Brian Abrahams of "RBC Capital" Maintained at Buy with Increased Target to $265 on, Thursday, December 2nd, 2021
- Brian Skorney of "Baird" Maintained at Buy and Held Target at $240 on, Thursday, December 2nd, 2021
- Debjit Chattopadhyay of "Guggenheim" Maintained at Strong Buy with Increased Target to $286 on, Wednesday, December 1st, 2021
- Robyn Karnauskas of "Truist Securities" Maintained at Strong Buy with Increased Target to $341 on, Wednesday, December 1st, 2021
